Geographic Information and Concentrations (Tables)

12 Months Ended

Dec. 31, 2023

Risks and Uncertainties [Abstract]

Schedule of Revenue by Geographic Areas

A summary of our revenue by geographic areas for the years ended December 31, 2023, 2022 and 2021, is as follows (in thousands):

	Year Ended December 31,
	2023		2022		2021
United States (1)	$	83,276	$	15,600	$	—
International:
Asia Pacific (2)	41,121		36,527		10,084
North America (3)	59		31		13
Total revenue	$	124,456	$	52,158	$	10,097

(1)Revenues from the United States are primarily comprised of amounts earned from sales of IBSRELA and XPHOZAH, as well as the upfront license fee from the METiS Agreement.

(2)Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 Kyowa Kirin Agreement, the 2019 Kyowa Kirin Agreement and the Fosun Agreement.

(3)Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.

Schedule of Revenues from Customers and Collaboration Partnerships

Revenue from the following Customers who contributed greater than 10% of our gross product revenue during the years ended December 31, 2023 and 2022 as a percentage of total gross product revenue was as follows:

	Year Ended December 31,
	2023		2022
BioRidge Pharma, LLC	26.3	%	—	%
Cardinal Health	21.6	%	23.1	%
AmerisourceBergen Drug Corporation	20.9	%	26.8	%
McKesson Corporation	17.2	%	21.6	%

Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December 31, 2023, 2022 and 2021 were as follows:

	Year Ended December 31,
	2023		2022		2021
Kyowa Kirin	29.0	%	70.0	%	100.0	%
Bioridge Phama	24.0	%	3.2	%	—	%
Cardinal	19.8	%	9.6	%	—	%
AmerisourceBergen Drug Corporation	19.1	%	11.1	%	—	%
McKesson	15.7	%	8.9	%	—	%